Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Tonix Pharmaceuticals Holding Corp. (TNXP)

1.4   0.03 (2.19%) 08-14 12:33
Open: 1.39 Pre. Close: 1.37
High: 1.43 Low: 1.36
Volume: 2,690,783 Market Cap: 60(M)
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.43 - 1.44 1.44 - 1.45
Low: 1.34 - 1.35 1.35 - 1.36
Close: 1.39 - 1.4 1.4 - 1.42

Technical analysis

as of: 2022-08-12 4:25:56 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.14     One year: 2.61
Support: Support1: 1.19    Support2: 0.99
Resistance: Resistance1: 1.83    Resistance2: 2.24
Pivot: 1.63
Moving Average: MA(5): 1.41     MA(20): 1.54
MA(100): 3.16     MA(250): 9.44
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 17.4     %D(3): 20.3
RSI: RSI(14): 42.1
52-week: High: 24.95  Low: 0.46
Average Vol(K): 3-Month: 11,167 (K)  10-Days: 11,537 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TNXP ] has closed above bottom band by 16.8%. Bollinger Bands are 55.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Thu, 11 Aug 2022
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Up 204.6% in July - Defense World

Mon, 01 Aug 2022
TNXP, GOVX, VRAX stocks rally as New York calls outbreak public emergency (NASDAQ:TNXP) - Seeking Alpha

Sun, 31 Jul 2022
Tonix Pharmaceuticals (TNXP) Stock: Why It Fell 10.16% - Pulse 2.0

Fri, 29 Jul 2022
Thinking about buying stock in Intel Corp, Thermogenesis, SIGA Technologies, Tonix Pharmaceuticals, or Sunrun? - PR Newswire

Thu, 28 Jul 2022
TNXP gains on partnership to study monkeypox vaccine in H1 2023 (NASDAQ:TNXP) - Seeking Alpha

Wed, 27 Jul 2022
Tonix Pharmaceuticals (NASDAQ:TNXP) Raised to “Sell” at StockNews.com - Defense World

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 32 (M)
Shares Float 19 (M)
% Held by Insiders 0 (%)
% Held by Institutions 9.6 (%)
Shares Short 775 (K)
Shares Short P.Month 1,560 (K)

Stock Financials

EPS -7.51
EPS Est Next Qtl -0.75
EPS Est This Year -3.02
EPS Est Next Year -2.48
Book Value (p.s.) 12.03
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -30.1
Return on Equity (ttm) -51
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.09
Qtrly Earnings Growth 0
Operating Cash Flow -86 (M)
Levered Free Cash Flow -101 (M)

Stock Valuations

PE Ratio -0.19
PEG Ratio 0
Price to Book value 0.11
Price to Sales 0
Price to Cash Flow -0.52

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-10-31
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.